Email
Password
Remember meForgot password?
    Log in with Twitter
| Press Release

Canbiola, Inc. (CANB) Announces the Addition of Dr. Channing Coe to the Medical Advisory Board

HICKSVILLE, NY / ACCESSWIRE / February 13, 2018 / Canbiola, Inc. (OTC PINK: CANB), in its continuing effort to attract and partner with industry experts in the Global Health and Wellness field, is proud to announced today that Dr. Channing Coe is joining the Medical Advisory Board and has also signed on as a Distributor. Dr. Coe stated, "I am pleased and honored to join the Medical Advisory Board at Canbiola. I am very encouraged with the benefits of Canbiola's CBD products and the potential for therapy with a wide range of female medical issues. The research and dedication of Canbiola to further our understanding of the medical benefits of CBD are extremely important to my patients' medical well-being."

Marco Alfonsi, Canbiola CEO, stated, "We are continuing to execute our plan to strengthen not only our Medical Advisory Board but also our distribution network. With the addition of Dr. Coe, we have added the 6th doctor to our Medical Advisory Board and believe this last addition will enhance our product development in new areas and further grow sales and geographically expand our client base."

Dr. Coe joins a medical advisory team that already has the following members:

About Dr. Channing Coe, MD. / Medical Advisor

Dr. Coe is a practicing Obstetrician and Gynecologist with a special focus on Robotic Minimally Invasive Surgery. His practice also focuses on treating women with chronic pain, endometriosis, and menstrual and menopausal symptoms. Dr. Coe incorporates Eastern and Western medicine as well as nutritional and herbal supplements to help patients realize their true potential.

Certifications and Training:

  • Doctor of Medicine 1998 - St Georges University
  • Residency - Obstetrics & Gynecology - St. Joseph's/Columbia/NYU 2002
  • Chief Resident Ob/Gyn 2002
  • Certified in Minimally Invasive Laparoscopic Surgery
  • Active Private Practice since 2002
  • Robotic Surgical Proctor since 2009

Member of American College of Obstetrics & Gynecology
Member of Society of Laparoendoscopic Surgeons
Member of American Medical Association

Canbiola will be attending the Integrative Healthcare Symposium Annual Conference on February 22-24, 2018 in New York City. Come join us and learn about the benefits of our products. (Booth # 638)

About Canbiola, Inc.

Canbiola, Inc. is a public company trading under symbol CANB.

Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states. The company has already launched several products found at www.canbiola.com.

The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.

Forward-Looking Statements and Risks and Uncertainties

Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

CONTACT INFORMATION

Canbiola Investor Relation
Email: IR@canbiola.com
Phone: (516) 595-9544
website: http://www.canbiola.com
Follow us on Twitter and Facebook

SOURCE: Canbiola, Inc.

Latest News
Top News